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Correspondence Left Bundle Branch Block in Non–ST-Segment
Elevation Acute Coronary Syndromes
Incidence, Angiographic Characteristics, and Clinical OutcomesTo the Editor: Acute coronary syndrome (ACS) patients present-
ing with left bundle branch block (LBBB) have higher mortality
rates and worse overall outcomes than patients without LBBB
(1,2). We compared clinical characteristics of 29,176 patients with
and without LBBB enrolled in non–ST-segment elevation
(NSTE) ACS clinical trials of antithrombotic therapy and ex-
plored the relationship of LBBB with outcomes.
We used 5 trials: GUSTO IIb (Global Use of Strategies to
Open Occluded Arteries in Acute Coronary Syndromes, NSTE
cohort) (n  8,011, 27.5%), PARAGON-A (Platelet IIb/IIIa
Antagonist for the Reduction of Acute Coronary Syndrome
Events in a Global Organization Network A) (n  2,282, 7.8%),
PARAGON-B (Platelet IIb/IIIa Antagonist for the Reduction of
Acute Coronary Syndrome Events in a Global Organization
Network B) (n  5,224, 17.9%), SYNERGY (Superior Yield of
he New Strategy of Enoxaparin, Revascularization and Glycopro-
ein IIb/IIIa Inhibitors) (n  4,256, 14.6%), and EARLY ACS
Early versus Delayed, Provisional Eptifibatide in Acute Coronary
yndromes) (n  9,403, 32.2%). LBBB status was identified on
the case report form and/or by the electrocardiogram core labora-
tory. Inclusion of patients with LBBB in these trials was generally
by investigator discretion. If LBBB was known to be new or
believed to represent an ST-segment elevation MI (STEMI)
equivalent, the patient was excluded. Angiographic and echocar-
diographic data were reported on the case report form or obtained
from a core angiography laboratory.
Our primary analysis examined 1-year mortality among survi-
vors to hospital discharge (n  24,848). We also examined
in-hospital mortality (n  25,934) and death or MI from hospital
ischarge to 30 days post-discharge among patients who survived
vent free to hospital discharge (n  23,044).
Of 29,176 total patients, 27,832 (95.4%) had information on
LBBB at baseline; LBBB was present in 490 (1.8%). LBBB
patients were older, were more often female, had more comorbidi-
ties, and had a higher Killip class. In a subgroup with in-hospital
assessment, they also had a lower left ventricular ejection fraction
(40% vs. 55%, p  0.001). Among 11,083 patients who had
coronary angiographic data available (125 with and 10,958 without
LBBB), right coronary artery lesion severity was greater among
those with LBBB than without (80% vs. 72%, p  0.032). Lesion
severity was similar for the left anterior descending (LAD), left
main, and left circumflex coronary arteries. Overall, 29.3% (3,242
of 11,083) had 100% occlusion in 1 main coronary vessel.
Among patients with LAD lesions, more patients with LBBB than
without had total LAD occlusion (26.8%, 19 of 71 vs. 14.9%,
1,265 of 8,467; p  0.0055).
Patients with LBBB had greater in-hospital mortality than
those without (4.3% vs. 2.6%), but the difference was not signifi-cant after adjustment for baseline characteristics (odds ratio: 0.99,
95% confidence interval [CI]: 0.62 to 1.59). Death or MI at 30
days post-discharge was also similar between groups (1.6% vs.
1.4%; adjusted odds ratio: 0.94, 95% CI: 0.43 to 2.05). Mortality
between hospital discharge and 1-year post-discharge was higher
among patients with LBBB at discharge (13.6%) than without
(4.3%) (Fig. 1). After adjustment, 1-year mortality was nearly
2-fold greater among LBBB patients (hazard ratio: 1.84, 95% CI:
1.4 to 2.4). Results were similar in sensitivity analyses using LBBB
at baseline instead of discharge.
LBBB has been associated with higher long-term mortality
among acute MI patients; yet it is less certain whether LBBB
independently predicts mortality (2). LBBB has not been studied
in solely NSTE ACS populations. In mixed STEMI and NSTE
ACS populations, there has been no clear association between
LBBB and 1-year mortality (3). We demonstrated that LBBB at
discharge was independently associated with nearly 2-fold higher
1-year mortality among NSTE ACS patients, but found no
significant association with in-hospital or short-term outcomes.
This contrasts with STEMI, in which LBBB patients had higher
short-term mortality and in-hospital complications (1).
Lower left ventricular ejection fraction in the LBBB population
could help to explain worse 1-year mortality. No data were
available on use of implantable cardiac defibrillator devices or
resynchronization therapy, which could additionally have affected
this observed association.
Nearly twice as many LBBB patients had total LAD occlusion
versus those without LBBB (26.8% vs. 14.9%). We could not
distinguish between those with chronic occlusion (with collateral
flow) versus acute (i.e., misdiagnosed STEMI), beyond presuming
previous coronary artery bypass graft (52.6% [10 of 19] with LBBB
vs. 46.2% [584 of 1,265] without) represented revascularized
LAD. Electrocardiograms were not available to determine Sgar-
bossa criteria; thus, we could not determine based on these criteria
whether some LBBB patients represented patients with possible
STEMI (4). Further, there is not consensus that LBBB is a marker
of acute MI or coronary disease severity among patients presenting
with potentially ischemic symptoms (5). However, the more
frequent total LAD occlusion and more severe coronary lesions we
observed illustrate the importance of coronary angiography in
NSTE ACS patients with LBBB.
In this retrospective study, we could not account for unmea-
sured confounders, and cause–effect relationships cannot be estab-
lished. LBBB was classified by individual investigators, and pro-
tocols varied by trial – potentially introducing selection bias or
misclassification of some STEMI patients as having NSTE ACS.
We were unable to adjust for severity of coronary disease (partic-
ularly in LAD), which could contribute to differences in mortality.
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April 2, 2013:1461–8There were few patients with LBBB and relatively few events,
limiting power to detect differences between those with and
without LBBB.
LBBB patients were older and had more comorbidities than
those without LBBB. Short-term and in-hospital ischemic out-
comes were similar, but LBBB patients had nearly 2-fold higher
1-year mortality after adjustment for other factors. Thus, it may be
reasonable to consider LBBB in addition to other factors to
identify NSTE ACS patients at higher longer-term risk.
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Single Exhaled Breath Metabolomic
Analysis Identifies Unique Breathprint inHeart FailureTo the Editor: Acute decompensated heart failure (ADHF) is the
ost common indication for hospital admission, particularly in the
lderly, yet the identification of those with impending decompen-
ation using conventional clinical methods is unreliable and fre-
uently leaves insufficient lag time for therapeutic interventions
1). Exhaled breath constitutes a complex mixture of hundreds of
olatile organic compounds (VOCs) that could potentially be used
s a safe and noninvasive method of diagnostic and therapeutic
onitoring (2). Previous research studies have identified elevated
cetone, pentane, and nitric oxide levels in exhaled breath in the
etting of HF correlated with disease severity (3–5). Selected
ion-flow tube mass-spectrometry (SIFT-MS) combines a fast flow
tube technique with quantitative mass spectrometry that is ideally
suited for exhaled breath analysis because it allows for the analysis
of small and humid samples without the need for cumbersome
sample preparation or calibration (6). Scan times are relatively
brief, thus facilitating high throughput and serial comparisons.
Figure 1 Canonical Discriminant Analysis: ADHF Versus Non-HF
Canonical discriminant analysis using 5 selected mass scanning ion peaks was
subjects (blue) and 16 controls (red). This ADHF “breathprint” was then used
misclassifications.Using this technology, we conducted a prospective, single-center
cohort study to assess the feasibility of exhaled breath analysis to
identify patients admitted for ADHF. The study protocol was
approved by the Cleveland Clinic Institutional Review Board. We
recruited 25 consecutive patients admitted with ADHF as their
primary diagnosis (mean left ventricular ejection fraction 27 
13%, median N-terminal pro–B-type natriuretic peptide level 954
pg/ml) and a control group of 16 subjects admitted with non-
ADHF cardiovascular diagnoses and who had no clinical evidence
of systemic or venous congestion at the time of enrollment.
Indications for hospitalization in the control group included
unstable angina or non–ST-segment elevation myocardial infarc-
tion (6 of 16), conduction disorders (3 of 16), hypertensive
emergency (3 of 16), atrial tachyarrhythmia (2 of 16), or stable angina
(2 of 16). All analyses were performed using JMP Pro 9.0 (SAS
Institute, Cary, North Carolina). As expected, there were significant
(p 0.01) baseline differences in the frequency of hypertension (54%
trols
rmed in a training cohort of 25 acute decompensated heart failure (ADHF)
ssify an independent validation cohort of 36 ADHF subjects (green) with noCon
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